New

Uncategorized

Braftovi 75mg Capsule

₹ 0.00₹ 0.00

Brand: Braftovi

Generic: Encorafenib

Manufacturer: Pierre Fabre Medicament

Drug class: BRAF kinase inhibitor or multikinase inhibitor.

Description

Introduction to Braftovi 75mg Capsule

Braftovi 75mg Capsule is a prescription anticancer medicine containing encorafenib 75mg, a targeted therapy known as a BRAF kinase inhibitor. It is used in combination with other anticancer medicines to treat certain cancers associated with specific BRAF mutations, including unresectable or metastatic melanoma, BRAF V600E-positive metastatic colorectal cancer (CRC), and BRAF V600E-positive metastatic non-small cell lung cancer (NSCLC), according to the applicable approved indication.

Encorafenib works by inhibiting abnormal BRAF signalling involved in cancer-cell growth and proliferation. By targeting this pathway, Braftovi may help slow the growth and progression of cancer cells carrying the relevant BRAF mutation. Treatment with Braftovi 75mg should be prescribed and monitored by an experienced oncology specialist after appropriate diagnostic testing.

Uses of Braftovi 75mg Capsule

Braftovi 75mg Capsule contains encorafenib, a targeted cancer medicine that works by inhibiting abnormal BRAF kinase activity. It is used in combination with other anticancer medicines to treat certain cancers associated with specific BRAF mutations. Braftovi should only be used after appropriate mutation testing and under the supervision of a qualified oncologist.

1. Braftovi 75mg for Melanoma

Braftovi, in combination with binimetinib, is used to treat unresectable or metastatic melanoma in patients whose tumors have a BRAF V600E or V600K mutation, as confirmed by an appropriate approved diagnostic test.

This combination targets the abnormal BRAF/MAPK signalling pathway involved in the growth of BRAF-mutated melanoma cells.

2. Braftovi 75mg for Metastatic Colorectal Cancer

Braftovi is used in combination with cetuximab-based treatment for adults with metastatic colorectal cancer (mCRC) whose tumors have a BRAF V600E mutation.

Depending on the approved treatment setting, Braftovi may be combined with cetuximab and fluorouracil-based chemotherapy or used with cetuximab following prior systemic therapy. The specific treatment regimen is determined by the treating oncologist.

3. Braftovi 75mg for Non-Small Cell Lung Cancer (NSCLC)

Braftovi, in combination with binimetinib, is indicated for adults with metastatic non-small cell lung cancer (NSCLC) that carries a BRAF V600E mutation.

Before treatment, the presence of the relevant BRAF mutation should be confirmed using an appropriate diagnostic test.

Who Can Use Braftovi 75mg?

Braftovi is intended for patients with cancers carrying the specific BRAF mutations covered by its approved indications. Braftovi is not indicated for BRAF wild-type melanoma, colorectal cancer, or NSCLC under these indications. Mutation testing should therefore be performed before treatment.

Important Information About Braftovi Uses

Braftovi 75mg is not normally used alone for its approved indications. It is administered as part of specific combination treatment regimens, such as:

• Braftovi + Binimetinib — certain BRAF V600E/V600K-mutated melanoma and BRAF V600E-mutated metastatic NSCLC
• Braftovi + Cetuximab ± fluorouracil-based chemotherapy — certain BRAF V600E-mutated metastatic colorectal cancer

The appropriate combination, dosage, and duration of treatment depend on the cancer type, BRAF mutation status, previous treatment, and the patient’s overall clinical condition.

Important: Braftovi 75mg Capsule is a prescription anticancer medicine. It should be taken only according to the treatment plan prescribed by an oncologist. Do not start, stop, or change the dose without medical advice.

Therapeutic Effects of Braftovi 75mg Capsule

Braftovi 75mg Capsule contains encorafenib, a targeted anticancer medicine that selectively inhibits BRAF kinase. It works by blocking abnormal signalling through the RAF/MEK/ERK (MAPK) pathway, which plays an important role in the growth and survival of cancer cells with specific BRAF mutations.

Encorafenib has demonstrated activity against several mutated forms of BRAF, including BRAF V600E and V600K. By suppressing BRAF-driven signalling, Braftovi can help inhibit the proliferation of cancer cells carrying these mutations.

Interaction of Braftovi 75mg Capsule with Other Drugs

Braftovi 75mg Capsule (encorafenib) can interact with certain medicines, which may change the amount of encorafenib in the blood or affect the effectiveness and safety of other medicines. Braftovi is primarily metabolized by the CYP3A4 enzyme, so medicines that strongly or moderately inhibit or induce CYP3A4 may significantly affect encorafenib exposure.

Before starting Braftovi 75mg, tell your doctor about all prescription medicines, over-the-counter medicines, vitamins, herbal products, and supplements you are taking.

How to Take Braftovi 75mg Capsule

Take Braftovi 75mg Capsule exactly as prescribed by your doctor. Swallow the capsule whole with water. It can be taken with or without food, preferably at the same time each day.

Do not crush, chew, or open the capsule unless your doctor specifically advises you to do so. The dosage and duration of treatment depend on your type of cancer and the other medicines used with Braftovi.

If you miss a dose, follow your doctor’s instructions. If you vomit after taking Braftovi, do not take an extra dose. Continue with your next scheduled dose.

Avoid grapefruit and grapefruit juice during treatment, as they may affect the level of encorafenib in your body.

Always follow your oncologist’s instructions and do not change or stop your Braftovi 75mg treatment without medical advice.

Safety Advice for Braftovi 75mg Capsule

• Pregnancy: Braftovi 75mg Capsule may harm an unborn baby. Inform your doctor if you are pregnant, planning pregnancy, or could become pregnant. Use effective contraception as advised by your doctor.
• Breastfeeding: Do not breastfeed during treatment with Braftovi and for the period recommended by your doctor after the last dose.
• Heart Problems: Tell your doctor if you have any heart condition or abnormal heart rhythm before taking Braftovi. Your heart function may need to be monitored during treatment.
• Liver Problems: Inform your doctor if you have liver disease. Liver function tests may be required during treatment.
• Eye Problems: Contact your doctor if you develop vision changes, eye pain, redness, or other new eye symptoms while taking Braftovi.
• Skin Changes: Report new or changing skin lesions, unusual growths, or persistent skin changes to your doctor. Regular skin examinations may be recommended.
• Bleeding: Tell your doctor if you experience unusual or severe bleeding, such as blood in the stool, urine, or vomit.
• Medicines: Inform your doctor about all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements you take. Some medicines can interact with encorafenib.
• Grapefruit: Avoid grapefruit and grapefruit juice during treatment unless your doctor specifically advises otherwise.
• Driving: Braftovi may cause tiredness, dizziness, or vision problems in some patients. Avoid driving or operating machinery if you experience these effects.
• Dose: Take Braftovi exactly as prescribed. Do not change the dose or stop treatment without consulting your oncologist.
• Medical Supervision: Braftovi 75mg Capsule is a prescription anticancer medicine and should be used under the supervision of a qualified healthcare professional.

Side Effects of Braftovi 75mg Capsule

Braftovi 75mg Capsule contains encorafenib, a targeted cancer medicine used in combination with other medicines to treat certain cancers. Like all medicines, Braftovi may cause side effects, although not everyone experiences them.

Common Side Effects

Some commonly reported side effects include:

• Tiredness or fatigue
• Nausea and vomiting
• Diarrhea or constipation
• Abdominal pain
• Joint or muscle pain
• Headache
• Dizziness
• Skin rash
• Dry or itchy skin
• Hair loss
• Reduced appetite
• Swelling of the hands or feet

These side effects may vary depending on the other cancer medicines used with Braftovi.

Serious Side Effects

Braftovi can sometimes cause serious side effects that require medical attention. Contact your doctor promptly if you experience:

• Unusual bleeding
• Severe or persistent skin changes
• Changes in vision or eye pain
• Chest pain, shortness of breath, or unusual swelling
• Severe abdominal pain
• Yellowing of the skin or eyes
• Severe or persistent diarrhea or vomiting
• Fast, irregular, or unusual heartbeat

Braftovi may also cause serious problems involving the heart, liver, eyes, skin, and other organs. Your doctor may perform regular tests during treatment to monitor your health.